Liposarcoma - Pipeline Insight, 2025
Description
DelveInsight’s, “Liposarcoma - Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Liposarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Liposarcoma: Overview
Liposarcoma is a rare and heterogeneous group of malignant tumors that arise from adipose (fat) tissue, representing approximately 13-20% of all soft tissue sarcomas. It is categorized into four subtypes based on histological characteristics: well-differentiated liposarcoma (WDLS) or atypical lipomatous tumor (ALT), dedifferentiated liposarcoma (DDLS), myxoid liposarcoma (MLS), and pleomorphic liposarcoma (PLS), with WDLS/ALT being the most common. Due to its rarity and complex nature, liposarcoma diagnosis can be challenging, often leading to misdiagnosis in up to 30% of cases. This diagnostic difficulty, along with limited treatment options, highlights the need for continued research and improved clinical strategies to enhance early detection and therapeutic outcomes for patients. Current treatment modalities include surgery, radiation therapy, and chemotherapy, though the prognosis remains variable depending on the subtype and stage of disease. Early detection and accurate diagnosis are critical for improving patient outcomes and survival rates.
Liposarcomas often present without noticeable symptoms, but a visible lump may develop under the skin, typically painless in the early stages. Clear warning signs include the appearance of a new lump or the persistent growth of an existing one, pain or numbness around the lump, and signs of internal bleeding, such as blood in the stool or vomit. Symptoms can vary depending on the location of the tumor. In the limbs, liposarcomas may cause a growing mass, pain, swelling, and weakness in the affected limb. When located in the abdomen, they may lead to abdominal pain, swelling, early satiety, constipation, and blood in the stool. As the tumor grows, it may press on surrounding tissues, further causing discomfort and impairment in function, which can lead to more noticeable symptoms. Early detection is crucial for better management and treatment outcomes.
The exact cause of liposarcoma remains unclear, but it is believed to result from genetic changes in fat cells' DNA. These changes cause the cells to transform into cancerous cells, leading to uncontrolled growth and division. The altered DNA prevents these cancer cells from dying as healthy cells would in their normal life cycle. In some cases, the cancerous cells remain localized, forming a tumor that grows larger over time. However, in other types of liposarcoma, the cancer cells can break away from the original tumor and spread to other parts of the body, a process known as metastasis. While specific risk factors are not fully understood, exposure to radiation, certain genetic conditions, and long-term exposure to toxic chemicals are thought to increase the risk of developing liposarcoma.
To diagnose liposarcoma, doctors typically start with a biopsy, which involves removing a sample of suspicious tissue either through a needle or during surgery. A pathologist examines the tissue under a microscope to check for cancer cells. If liposarcoma is confirmed, additional imaging tests such as X-rays, MRI, CT scans, or ultrasound may be ordered to assess the size of the tumor and determine how far the cancer has spread. In some cases, a PET scan may also be used. The biopsy sample is sent to a laboratory for further analysis, allowing doctors to better understand the cancer's characteristics, prognosis, and to help plan appropriate treatment.
Treatment for liposarcoma typically begins with surgery to remove the tumor, with the goal of excising all cancerous cells while preserving surrounding organs. In cases where the tumor involves nearby organs, other treatments like radiation or chemotherapy may be used to shrink the tumor before surgery, making it easier to remove. Radiation therapy uses high-energy beams to kill cancer cells and may be employed both before and after surgery to target remaining cancer cells. Chemotherapy, which uses powerful drugs to kill cancer cells, is not effective for all types of liposarcoma but may be used in combination with surgery or radiation to treat the cancer. The treatment plan is tailored to the specific characteristics of the tumor and the patient’s condition.
""Liposarcoma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Liposarcoma pipeline landscape is provided which includes the disease overview and Liposarcoma treatment guidelines. The assessment part of the report embraces, in depth Liposarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Liposarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Liposarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Liposarcoma Emerging Drugs
Further product details are provided in the report……..
Liposarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Liposarcoma drugs segregated based on following parameters that define the scope of the report, such as:
Liposarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Liposarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Liposarcoma drugs.
Liposarcoma Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Liposarcoma: Overview
Liposarcoma is a rare and heterogeneous group of malignant tumors that arise from adipose (fat) tissue, representing approximately 13-20% of all soft tissue sarcomas. It is categorized into four subtypes based on histological characteristics: well-differentiated liposarcoma (WDLS) or atypical lipomatous tumor (ALT), dedifferentiated liposarcoma (DDLS), myxoid liposarcoma (MLS), and pleomorphic liposarcoma (PLS), with WDLS/ALT being the most common. Due to its rarity and complex nature, liposarcoma diagnosis can be challenging, often leading to misdiagnosis in up to 30% of cases. This diagnostic difficulty, along with limited treatment options, highlights the need for continued research and improved clinical strategies to enhance early detection and therapeutic outcomes for patients. Current treatment modalities include surgery, radiation therapy, and chemotherapy, though the prognosis remains variable depending on the subtype and stage of disease. Early detection and accurate diagnosis are critical for improving patient outcomes and survival rates.
Liposarcomas often present without noticeable symptoms, but a visible lump may develop under the skin, typically painless in the early stages. Clear warning signs include the appearance of a new lump or the persistent growth of an existing one, pain or numbness around the lump, and signs of internal bleeding, such as blood in the stool or vomit. Symptoms can vary depending on the location of the tumor. In the limbs, liposarcomas may cause a growing mass, pain, swelling, and weakness in the affected limb. When located in the abdomen, they may lead to abdominal pain, swelling, early satiety, constipation, and blood in the stool. As the tumor grows, it may press on surrounding tissues, further causing discomfort and impairment in function, which can lead to more noticeable symptoms. Early detection is crucial for better management and treatment outcomes.
The exact cause of liposarcoma remains unclear, but it is believed to result from genetic changes in fat cells' DNA. These changes cause the cells to transform into cancerous cells, leading to uncontrolled growth and division. The altered DNA prevents these cancer cells from dying as healthy cells would in their normal life cycle. In some cases, the cancerous cells remain localized, forming a tumor that grows larger over time. However, in other types of liposarcoma, the cancer cells can break away from the original tumor and spread to other parts of the body, a process known as metastasis. While specific risk factors are not fully understood, exposure to radiation, certain genetic conditions, and long-term exposure to toxic chemicals are thought to increase the risk of developing liposarcoma.
To diagnose liposarcoma, doctors typically start with a biopsy, which involves removing a sample of suspicious tissue either through a needle or during surgery. A pathologist examines the tissue under a microscope to check for cancer cells. If liposarcoma is confirmed, additional imaging tests such as X-rays, MRI, CT scans, or ultrasound may be ordered to assess the size of the tumor and determine how far the cancer has spread. In some cases, a PET scan may also be used. The biopsy sample is sent to a laboratory for further analysis, allowing doctors to better understand the cancer's characteristics, prognosis, and to help plan appropriate treatment.
Treatment for liposarcoma typically begins with surgery to remove the tumor, with the goal of excising all cancerous cells while preserving surrounding organs. In cases where the tumor involves nearby organs, other treatments like radiation or chemotherapy may be used to shrink the tumor before surgery, making it easier to remove. Radiation therapy uses high-energy beams to kill cancer cells and may be employed both before and after surgery to target remaining cancer cells. Chemotherapy, which uses powerful drugs to kill cancer cells, is not effective for all types of liposarcoma but may be used in combination with surgery or radiation to treat the cancer. The treatment plan is tailored to the specific characteristics of the tumor and the patient’s condition.
""Liposarcoma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Liposarcoma pipeline landscape is provided which includes the disease overview and Liposarcoma treatment guidelines. The assessment part of the report embraces, in depth Liposarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Liposarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Liposarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Liposarcoma.
This segment of the Liposarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Liposarcoma Emerging Drugs
- Brigimadlin: Boehringer Ingelheim
- APG-115: Ascentage Pharma Group Inc.
- CAR-GPC3 T Cells: Sotio Biotech Inc.
- BTX-A51: Edgewood Oncology Inc.
Further product details are provided in the report……..
Liposarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Liposarcoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Liposarcoma
- There are approx. 15+ key companies which are developing the therapies for Liposarcoma. The companies which have their Liposarcoma drug candidates in the most advanced stage, i.e. Phase III include, Boehringer Ingelheim.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Liposarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Liposarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Liposarcoma drugs.
Liposarcoma Report Insights
- Liposarcoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Liposarcoma drugs?
- How many Liposarcoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Liposarcoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Liposarcoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Liposarcoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Boehringer Ingelheim
- Ascentage Pharma Group Inc.
- Edgewood Oncology Inc.
- Shanghai Pharmaceuticals Holding Co., Ltd
- Salarius Pharmaceuticals, LLC
- Lamassu Bio Inc
- Pfizer
- Valo Therapeutics Oy
- OncoResponse, Inc.
- Adaptimmune
- Incyte Corporation
- Daiichi Sankyo
- Numab Therapeutics AG
- HRYZ Biotech Co.
- Sotio Biotech Inc.
- Brigimadlin
- APG-115
- BTX-A51
- SPH4336
- Seclidemstat
- SA53-OS
- PF-07220060
- PeptiCRAd-1
- OR2805
- Letetresgene autoleucel
- INCMGA00012
- DS-2243a
- NM32-2668
- MASCT-I
- CAR-GPC3 T Cells
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Liposarcoma: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Liposarcoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Brigimadlin: Boehringer Ingelheim
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/II)
- Comparative Analysis
- APG-115: Ascentage Pharma Group Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- BTX-A51: Edgewood Oncology Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Liposarcoma Key Companies
- Liposarcoma Key Products
- Liposarcoma- Unmet Needs
- Liposarcoma- Market Drivers and Barriers
- Liposarcoma- Future Perspectives and Conclusion
- Liposarcoma Analyst Views
- Liposarcoma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
